BLK vs PFE: Which Is the Better Buy?

Side-by-side comparison of BlackRock, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-05-05.
BlackRock, Inc. · Financial Services
$1,042.85
+36.5% upside to fair value
Grade A High Quality
VS
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
BLK has more upside to fair value (+36.5%). PFE trades at a lower forward P/E (19.3x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric BLK PFE
Current Price $1,042.85 $26.33
Fair Value Estimate $1,423.18 $33.85
Upside to Fair Value +36.5% +28.6%
Market Cap $162.2B $149.8B
Forward P/E 25.9x 19.3x
EV / EBITDA 16.9x 12.9x
Price / Sales 6.3x 2.4x
Price / FCF 45.2x 16.5x
Revenue Growth YoY +28.3% -1.2%
Gross Margin 59.1% 70.3%
Operating Margin 29.9% 24.7%
Return on Equity 12.0% 8.7%
Dividend Yield 0% 0%
FCF Yield 2.21% 6.06%
Analyst Consensus Strong Buy Hold
Investment Thesis
BLK — BlackRock, Inc.
BlackRock, Inc. is the world's largest asset manager with over $14 trillion in assets under management, operating primarily in financial services and asset management. The company benefits from a durable competitive moat driven by its scale, technology platform Aladdin, and founder-led management with CEO Laurence D. Fink at the helm since inception. BlackRock exhibits strong fundamentals includi…
PFE — Pfizer Inc.
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
Metric BLK PFE
Zone Low $1,067.38 $25.39
Zone High $1,209.70 $28.77
In Buy Zone? Yes Yes
← BLK Research    PFE Research →    All Research